Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06750484 · ClinicalTrials.gov registry record · Phase 2
Trial of Trastuzumab Deruxtecan in Previously Treated HER2
A Phase 2 study of Breast Cancer Metastatic, sponsored by Yale University.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 2
- Study locations
NCT06750484: Recruiting Phase 2 study of Breast Cancer Metastatic, sponsored by Yale University.
NCT06750484 is a Phase 2 study of Breast Cancer Metastatic that is actively recruiting participants, run by Yale University. The registered enrollment target is 40 participants, below the 90-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target (56% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06750484, a Phase 2 study of Breast Cancer Metastatic, is actively recruiting participants, sponsored by Yale University.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.
Primary Outcome
The confirmed Objective Response Rate to Trastuzumab Deruxtecan by RECIST (Response Evaluation Criteria In Solid Tumors) defined as the cumulative rate of complete response (CR) rate and partial response (PR) rates, evaluated according to mRECIST v1.1
Conditions Studied
Interventions
- DRUG Trastuzumab Deruxtecan
Study Locations (2)
Connecticut
- Yale University - New Haven
New York
- University of Rochester Medical Center - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-06-20 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 2 |
What NCT06750484 shows while recruiting
NCT06750484 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 90-participant average among 17 other Breast Cancer Metastatic trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Breast Cancer Metastatic appearing as the primary indexed condition, and to 1 intervention - of which Trastuzumab Deruxtecan is the first listed.
NCT06750484 reports a single indexed study location in Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT06750484 about?
NCT06750484 is a clinical study titled "Trial of Trastuzumab Deruxtecan in Previously Treated HER2". The purpose of this study is to test the good and bad effects of a drug called trastuzumab deruxtecan (T-DXd) in adult patients with metastatic HER2-negative breast cancer and which patients might benefit the most from T-DXd.
What is the current status of trial NCT06750484?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-06-20. Estimated completion is 2028-12-31.
What conditions does trial NCT06750484 study?
This clinical trial studies the following conditions: Breast Cancer Metastatic.
What interventions are being tested in trial NCT06750484?
The interventions under investigation include: Trastuzumab Deruxtecan (DRUG).
Who is sponsoring clinical trial NCT06750484?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06750484 being conducted?
This trial has 2 study locations across Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer Metastatic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06750484's enrollment target sits among peer trials
40 11th of 17 higher than 7 of 17 other Breast Cancer Metastatic trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer Metastatic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study
ACTIVE NOT RECRUITING · Phase 2
-
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
COMPLETED · Phase 2
-
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
RECRUITING · Phase 1
-
Nutrition Awareness Among Women With Non-Metastatic Breast Cancer
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI